CompletedPhase 3NCT00278421
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Studying Anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Principal Investigator
- Michael G.M. Pfreundschuh, MD †Universitaetsklinikum des Saarlandes
- Intervention
- rituximab(biological)
- Enrollment
- 592 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2005 – 2018
Study locations (30)
- Haematologisch Onkologische Praxis, Aachen, Germany
- Klinikum Augsburg, Augsburg, Germany
- Klinikum Bayreuth, Bayreuth, Germany
- Haematologisch-Onkologische Schwerpunktpraxis - Weilheim, Berlin, Germany
- Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
- Franziskus Hospital, Bielefeld, Germany
- Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
- Staedtisches Klinikum Braunschweig, Braunschweig, Germany
- DIAKO Ev. Diakonie Krankenhaus gGmbH, Bremen, Germany
- Hospital Kuchwald Chemnitz, Chemnitz, Germany
- Praxis Fuer Haematologie Internistische Onkologie, Cologne, Germany
- Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany
- Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
- Praxis Dr. Rheinhold Siegmund - Dr. Matthias Penke, Damme, Germany
- Klinikum Dortmund, Dortmund, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00278421 on ClinicalTrials.govOther trials for Anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaCorvus Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT06494371A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06137144AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.AstraZeneca
- ACTIVE NOT RECRUITINGPHASE1NCT04526834Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaTessa Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT04881838CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCLChildren's Cancer Group, China
- ACTIVE NOT RECRUITINGPHASE2NCT02978625Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersNational Cancer Institute (NCI)
- RECRUITINGNCT04220970Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) RegistryThe Lymphoma Academic Research Organisation